{
    "2019-09-09": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study",
                "features": {
                    "keywords": [
                        "RET Inhibitor",
                        "Shrinks",
                        "Tumors",
                        "Lung Cancer"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Novartis Announces Positive Long-Term Data on Migraine Drug",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Positive",
                        "Long-Term",
                        "Migraine",
                        "Drug"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "[video]Eli Lilly's Must-Hold Level on Drug-Data Pullback",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Must-Hold",
                        "Drug-Data",
                        "Pullback"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-06-05",
                "original_text": "Eli Lilly Stock Shrugs Off Upbeat Drug Data",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Stock",
                        "Upbeat",
                        "Drug Data"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-07-12",
                "original_text": "Eli Lilly's Lung Cancer Treatment Candidate Shows Strong Results in Trial",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Lung Cancer",
                        "Treatment",
                        "Strong Results",
                        "Trial"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-08-25",
                "original_text": "Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Selpercatinib",
                        "LOXO-292",
                        "Objective Response Rate",
                        "Lung Cancer"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-09-10",
                "original_text": "Lilly's targeted RET drug shrinks tumors in lung cancer trial",
                "features": {
                    "keywords": [
                        "Lilly",
                        "RET drug",
                        "shrinks",
                        "tumors",
                        "lung cancer"
                    ],
                    "sentiment_score": 0.88,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}